Skip to content
10-Q

Quarterly Report

Kronos Bio, Inc.

0001741830-24-000034

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 60.09M sh
Short Term Investments Q1 2024 · Mar 31, 2024 $105.79M
Short Term Investments Q1 2024 · Dec 31, 2023 $108.67M
Current Liabilities Q1 2024 · Mar 31, 2024 $19.03M
Current Liabilities Q1 2024 · Dec 31, 2023 $24.7M
Total Liabilities Q1 2024 · Mar 31, 2024 $46.01M
Total Liabilities Q1 2024 · Dec 31, 2023 $54.2M
Current Assets Q1 2024 · Mar 31, 2024 $158.36M
Current Assets Q1 2024 · Dec 31, 2023 $178.78M
Total Assets Q1 2024 · Mar 31, 2024 $182.98M
Total Assets Q1 2024 · Dec 31, 2023 $213.28M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $64.33M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $61.65M
Shares Diluted restated Q1 2024 · Mar 31, 2023 57.15M sh
Capex Q1 2024 · Mar 31, 2023 $126K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$5.95M
Stockholders Equity Q1 2024 · Mar 31, 2023 $225.61M
Stockholders Equity Q1 2024 · Dec 31, 2022 $244.5M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.46
Eps Basic Q1 2024 · Mar 31, 2023 −$0.46
Sga Expense Q1 2024 · Mar 31, 2023 $10.06M
Rd Expense Q1 2024 · Mar 31, 2023 $19.66M
Net Income Q1 2024 · Mar 31, 2023 −$26.24M
Operating Income Q1 2024 · Mar 31, 2023 −$28.49M
Revenue Q1 2024 · Mar 31, 2023 $1.22M